The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
Glioblastoma (GBM) promotes immunosuppression through upregulation of PD-L1 and regulatory T cell (Treg) expansion, but the association of these suppressive factors has not been well elucidated. Here, we investigate a role of PD-L1 in expanding Tregs and the value of targeting the PD-1 receptor to i...
Main Authors: | Joseph DiDomenico, Jonathan B. Lamano, Daniel Oyon, Yuping Li, Dorina Veliceasa, Gurvinder Kaur, Leonel Ampie, Winward Choy, Jason B. Lamano, Orin Bloch |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-07-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1448329 |
Similar Items
-
Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01) -
Immune Checkpoints and Innovative Therapies in Glioblastoma
by: Massimo Romani, et al.
Published: (2018-10-01) -
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01) -
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01) -
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
by: Selina K. Wong, et al.
Published: (2021-11-01)